SAMHD1 and diffuse large B-cell lymphoma: Given our data showing that low SAMHD1 expression is associated with improved outcomes for DLBCL patients, it is possible that treatment regimens could be tailored to individualize DLBCL patient treatment based on SAMHD1 expression.